[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocritical-care\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocritical-care":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,81,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100640910","phase-2-feasibility-and-safety-of-targeting-neutral-vs-liberal-fluid-balance-in-traumatic-brain-injured-patients--limit-tbi-trial-100640910",false,"NCT07625995","Feasibility and Safety of Targeting Neutral vs Liberal Fluid Balance in Traumatic Brain Injured Patients- LIMIT-TBI Trial","Feasibility and Safety of Targeting Neutral vs Liberal Fluid Balance in Traumatic Brain Injured Patients: a Phase II Randomized Controlled Trial - LIMIT-TBI Trial","LIMIT-TBI","Inclusion Criteria:\n\n* Adult patients with traumatic brain injury (isolated or associated with extracranial injuries), with or without intracranial pressure monitoring\n* Admission to the intensive care unit\n* Age \\>18 years\n* Enrollment within 48 hours after ICU admission\n\nExclusion Criteria:\n\n* Enrollment in another clinical trial not approved for co-enrollment\n* Pregnancy or suspected pregnancy\n* Concomitant hemorrhagic shock expected to require surgical treatment within 24 hours from inclusion or requiring massive transfusion protocol\n* Hemodynamic instability at ICU admission, defined as heart rate \\>120 beats\u002Fmin and systolic arterial pressure \\\u003C100 mmHg despite at least 1 L of fluid resuscitation, or requirement for high-dose norepinephrine (\\>0.5 mcg\u002Fkg\u002Fmin) or any inotropic support\n* Need for continuous venovenous hemodiafiltration (CVVHDF) at admission\n* Expected survival \\\u003C48 hours","ALL","18 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The LIMIT-TBI trial is a multicenter, international, randomized, phase II clinical trial designed to evaluate the feasibility and safety of targeting a neutral fluid balance compared to standard care in critically ill adult patients with traumatic brain injury (TBI).\n\nFluid therapy is a cornerstone of TBI management, but optimal fluid balance remains uncertain, with both fluid overload and restriction potentially leading to adverse outcomes. This study aims to determine whether maintaining a daily fluid balance close to zero (±500 mL) during the first 5 days of ICU admission is achievable and safe.\n\nParticipants will be randomized within 48 hours of ICU admission to either a protocolized neutral fluid balance strategy or standard care. Outcomes include feasibility of achieving the target balance, organ complications, hemodynamic parameters, ICU resource utilization, and mortality and neurological outcomes up to 6 months.",[27,28,29,30],"Traumatic Brain Injury","Severe Traumatic Brain Injury","Acute Brain Injury","Neurocritical Care",[32,33,34,35,36],"Fluid Balance","Fluid Therapy","Hemodynamic Management","Feasibility Study","Intracranial Pressure","RECRUITING","2026-05-30",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":41},"2025-07-01",{"date":45,"type":21},"2029-02",{"name":47,"class":48},"Erasme University Hospital","OTHER",3,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100600048","effect-of-semi-elemental-enteral-nutrition-on-gastrointestinal-tolerance-in-patients-with-traumatic-brain-injury-100600048","NCT07092423","Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury.","The Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury: a Randomized Exploratory Study","SEMINAR","Inclusion Criteria:\n\n* Aged 18-75 years;\n* Clinically diagnosed with closed traumatic brain injury;\n* Glasgow Coma Scale (GCS) score ≤ 8;\n* Ability to initiate enteral nutrition within 48 hours post-injury;\n* Expected need for enteral nutrition support ≥3 days based on clinical assessment (Nutritional Risk Screening 2002 \\[NRS2002\\] score ≥3).\n\nExclusion Criteria:\n\n* GCS=3 with bilateral fixed and dilated pupils;\n* Hemodynamic instability or respiratory failure: mean arterial pressure \\\u003C70mmHg, PaO2\u002FFiO2\\\u003C150, PaCO2\\\u003C30 mmHg or \\>45 mmHg, or lactate \\>5 mmol\u002Fl;\n* Contraindications to both nasogastric and nasojejunal tube placement, or inability to complete tube placement within 48 hours of onset;\n* Contraindications to enteral nutrition therapy or semi-recumbent positioning;\n* Pre-existing intellectual disability or physical disability affecting outcome assessment;\n* Gastrointestinal abnormalities likely to affect gastrointestinal function, such as short bowel syndrome (defined as total small bowel length ≤122 cm), ulcerative colitis, Crohn's disease, or any form of ostomy;\n* Body mass index (BMI) \\\u003C18kg\u002Fm2;\n* Concomitant abdominal injury or extracranial injury with AIS score \\>3 in any region;\n* Presence of malignancy, severe cardiac insufficiency (ejection fraction \\\u003C50%), severe hepatic failure (Child-Pugh score ≥7), or severe renal failure (glomerular filtration rate ≤30 mL\u002Fmin or serum creatinine ≥4mg\u002FdL) at NICU admission;\n* Concurrent severe disease with expected survival ≤14 days;\n* Pregnancy, within 30 days postpartum, or breastfeeding;\n* Refusal of treatment or receipt of palliative care;\n* Patient or family declines informed consent;\n* Current participation in another interventional clinical trial.","75 Years",{"count":60,"type":21},100,[62],"NA","Study Objective This clinical trial primarily aims to investigate whether semi-elemental enteral nutrition (SEN) improves gastrointestinal tolerance in patients with severe traumatic brain injury (TBI) and to evaluate its impact on clinical outcomes. The safety profile of SEN will also be assessed.\n\nKey Research Questions Does SEN reduce the incidence of acute gastrointestinal injury (AGI) in severe TBI patients?\n\nStudy Design\n\nParticipants will be randomized 1:1 into either:\n\nIntervention group: Receives SEN initiated within 48 hours post-injury and continued for ≥7 days.\n\nControl group: Receives standard enteral nutrition over the same period.",[27,30,65],"Enteral Feeding Intolerance",[27,67,68,69,30,70],"Enteral Nutrition","Gastrointestinal Intolerance","Semi-elemental Formula","Prognosis","2026-04-26",{"date":73,"type":41},"2026-04-30",{"date":75,"type":41},"2025-05-18",{"date":77,"type":21},"2027-05-31",{"name":79,"class":48},"Tang-Du Hospital",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100601819","development-and-validation-of-a-prognostic-model-for-neurocritical-patients-using-multimodal-brain-monitoring-100601819","NCT07115459","Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring","Protocol for Developing and Validating a Multimodal Brain Monitoring-Based Prognostic Model for Neurocritical Patients: A Prospective, Observational, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Aged 18-80 years, no gender restrictions.\n2. Diagnosed with acute brain injury (ABI), including one of the following: large cerebral infarction, supratentorial large-volume intracerebral hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury, with imaging evidence (CT or MRI) supporting the diagnosis.\n3. On ICU admission, Glasgow Coma Scale (GCS) eye response = 1 (no eye opening) and motor score ≤ 5 (does not follow commands); or within 48 hours, neurological deterioration with no eye opening and motor score reduced to ≤ 5 (total GCS score ≤ 8).\n4. Able to undergo continuous multimodal monitoring, with an expected ICU stay of ≥72 hours.\n5. Informed consent signed by the family or legal representative.\n\nExclusion Criteria:\n\n1. Confirmed brain death on admission or imaging showing irreversible brain herniation.\n2. Severe trauma unrelated to brain injury (e.g., multiple fractures, spinal cord injuries, or visceral rupture) that may interfere with brain function monitoring or outcome assessment.\n3. Pre-existing severe neurological disorders such as epilepsy, severe encephalopathy, or chronic intracranial conditions (e.g., brain tumors or hydrocephalus).\n4. Inability to perform multimodal monitoring due to technical issues (e.g., equipment failure or sensor installation problems).\n5. Predicted survival time \\\u003C24 hours after admission, or family members choose to withdraw treatment.\n6. Refusal to participate in the study by the patient or their legal representative.","80 Years",{"count":90,"type":21},167,"OBSERVATIONAL","This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment decisions. The study is observational and involves no experimental interventions.",[94,30,95,96,97,28],"Acute Brain Injury Coma","Cerebral Infarction","Intracranial Hemorrhages","Subarachnoid Hemorrhage",[99,100],"Multimodal Brain Monitoring","Prognostic Model","NOT_YET_RECRUITING","2025-08-03",{"date":104,"type":41},"2025-08-11",{"date":106,"type":21},"2025-08-15",{"date":108,"type":21},"2026-11-15",{"name":110,"class":48},"Xiangya Hospital of Central South University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":80},"100534642","safety-and-efficacy-of-enhanced-recovery-after-surgery-in-neurocritical-care-100534642","NCT06241482","Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care","A Randomized Controlled Clinical Study on Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care Patients","Inclusion Criteria:\n\n* Age 18-75 years old\n* Patients with moderate or severe acute traumatic brain injury or cerebrovascular disease requiring neurosurgical intensive care treatment\n* Hospitalization time ≥ 1 week\n* The guardian is able to understand and actively cooperate in completing the project\n* The guardian signs an informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing non-surgical treatment\n* Patients diagnosed as brain death within the first 24 hours after admission to NICU\n* Patients undergoing cardiopulmonary resuscitation, maintenance dialysis, end-stage tumors, and disseminated cancer\n* Patients who withdraw treatment during hospitalization or are discharged automatically\n* Patients who underwent unplanned secondary surgery during the research process\n* Individuals who cannot be followed up during the research process",{"count":119,"type":21},80,[62],"Enhanced recovery after surgery (ERAS) is a strategy of perioperative management aimed to accelerate the rehabilitation of patients through various optimized perioperative managements as well as ongoing adherence to a patient-focused, multidisciplinary, and multimodal approach. Alleviating the injury and stress caused by surgery or disease is the core principle of ERAS, which has been shown to reduce complication rates after surgery, promote patient recovery, decrease hospital length of stay and reduce costs. ERAS has been widely applied in many surgical perioperative fields, and it has achieved remarkable effects. However, there are few applications of ERAS in neurosurgery, especially in clinical trials of neurocritical care patients.\n\nTherefore, the investigators attempt to conduct the study of ERAS in neurosurgical intensive patients using a series of optimized perioperative managements that have been verified to be effective by evidence-based medicine, and to evaluate the safety and effectiveness of ERAS in neurocritical care. The aim of this study is to explore the most suitable ERAS protocols to accelerate the postoperative rehabilitation process of neurocritical care patients, and to provide more evidence-based medicine for the effectiveness and safety of ERAS in neurosurgery.",[30,27,123,124],"Cerebrovascular Disease","Moderate or Severe Coma",[30,27,123],"2025-03-03",{"date":128,"type":41},"2025-03-04",{"date":130,"type":41},"2024-10-15",{"date":132,"type":21},"2027-04-30",{"name":134,"class":48},"Shanghai 6th People's Hospital"]